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CALCULATING HEMATOPOIETIC-MODE-LETHALITY RISK AVOIDANCE
ASSOCIATED WITH RADIONUCLIDE DECORPORATION COUNTERMEASURES
RELATED TO A RADIOLOGICAL TERRORISM INCIDENT
Bobby R. Scott  Lovelace Respiratory Research Institute
 This paper provides theoretical health-risk-assessment tools that are designed to facil-
itate planning for and managing radiological terrorism incidents that involve ingestion
exposure to bone-seeking radionuclides (e.g., radiostrontium nuclides). The focus is on
evaluating lethality risk avoidance (RAV; i.e., the decrease in risk) that is associated with
radionuclide decorporation countermeasures employed to remove ingested bone-seeking
beta and/or gamma-emitting radionuclides from the body. To illustrate the application of
tools presented, hypothetical radiostrontium decorporation scenarios were considered
that involved evaluating the hematopoietic-mode-lethality RAV. For evaluating the efficacy
of specific decorporation countermeasures, the lethality risk avoidance proportion (RAP;
which is the RAV divided by the total lethality risk in the absence of protective countermeasures) is
introduced. The lethality RAP is expected to be a useful tool for designing optimal
radionuclide decorporation schemes and for identifying green, yellow and red dose-rate
zones. For the green zone, essentially all of the lethality risk is expected to be avoided
(RAP = 1) as a consequence of the radionuclide decorporation scheme used. For the yel-
low zone, some but not all of the lethality risk is expected to be avoided. For the red zone,
none of the lethality risk (which equals 1) is expected to be avoided.
Keywords: Risk, radiation, radionuclide, lethality, countermeasures
INTRODUCTION
Recent events throughout the world underscore the growing threat of
different forms of terrorism, including radiological terrorism (Durante
and Manti 2002; Major 2002; Mettler and Voelz 2002; CRS 2004;
Augustine et al. 2005; González 2005; Bunn 2006; Dombroski and
Fischbeck 2006; Tofani and Bartolozzi 2008). This has stimulated
research on and development of medical countermeasures for protecting
humans against radiation harm, including harm resulting from use by ter-
rorist of a radioactivity dispersal device (RDD) (Goan 2001; NCRP 2001;
FAO 2002; Ansari 2004; Scott 2005). An RDD is any weapon designed to
disperse radioactivity, cause harm to humans, and possibly also have neg-
ative economic impact (e.g., render economically viable areas of a city
uninhabitable for extended periods of time). A dirty bomb is the most
well-known RDD.
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During a radiological terrorism incident, radionuclides could be
inhaled or ingested depending on the type of incident (e.g., dirty bomb
detonation; intentional food or beverage contamination with high levels
of radionuclides, etc.). Inhaling or ingesting large quantities of radionu-
clides could lead to lives lost among the general public from radiation-
induced deterministic effects as was illustrated in the case of the ingestion
route poisoning of Mr. Alexander Litvinenko in London in November of
2006 with polonium-210 (210Po) (Harrison et al. 2007; Scott 2007).
Deterministic effects are threshold-type effects that include lethal dam-
age to the bone marrow, lung, and gastrointestinal tract due to massive
cell killing. The effective management of such terrorist-invoked incidents
requires careful planning that includes considering the impact of coun-
termeasures likely to be employed to reduce the risk of harm to the gen-
eral public.
Pharmaceutical and other products are being developed (discussed
below) for possible employment as decorporating agents to facilitate
removal of radionuclides from the body in the event of a radiological ter-
rorism incident (Augustine et al. 2005). In addition, drug efficacy studies
using animal models of radionuclide decorporation currently are being
planned and carried out. However, essentially no research is being sup-
ported that relates to evaluating the expected lethality risk avoidance asso-
ciated with employment of decorporation protocols. Risk avoidance (RAV)
is defined as the amount of risk (on a scale from 0 to 1) that is avoided due to pro-
tective measures employed. A related concept, risk avoidance proportion (RAP)
is defined as the risk avoidance expressed as a proportion of the total risk
that would be expected in the absence of protective countermeasures
such as decorporation therapy.
Knowledge of lethality RAV associated with specific countermeasure
applications facilitates planning for and managing radiological terrorism
incidents that involve the intake of radionuclides. This paper introduces
a theoretical modeling framework for evaluating lethality RAV for radio-
logical incidents that involve the ingestion intake of bone-seeking
radionuclides. The focus here is on low linear-energy-transfer (LET) beta and/or
gamma-emitting radionuclides that deposit from the systemic circulation into the
skeleton and irradiate the radiosensitive bone marrow. Only ingested forms of
radiostrontium that are readily absorbed into the systemic circulation are
considered. For insoluble forms that are very poorly absorbed, gastroin-
testinal tract damage may be the main concern rather than damage to the
hematopoietic system.
The objective of the research discussed in this paper was to provide a
modeling framework under which one can evaluate the expected impact
of radionuclide decorporation therapy on avoiding the lethality risk for
the hematopoietic mode of death. Radiostrontium isotopes are considered
as representative beta/gamma emitting, bone-seeking radionuclides.
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We consider the very simple case in which a radiostrontium isotope is
deposited from the systemic circulation into the skeleton after ingestion
and the dose rate to bone marrow decreases as a single negative-expo-
nential function of time. The single negative-exponential characterization is but
a crude approximation that is used here for illustrative purposes to facilitate under-
standing the RAV/RAP modeling framework presented. The modeling results
presented in the main text and in the Appendix can be used along with
dosimetry software (to evaluate dose rates and cumulative doses to body
organs and tissue of interest) to conduct a formal risk assessment. While
the focus is on the hematopoietic mode of death, equations presented
also can be applied to other endpoints such as lethality via the pulmonary
mode.
The Most Important Radiostrontium Isotopes
There are 16 known radiostrontium isotopes. The most important for
the current consideration are Strontium-90 (90Sr, physical half-life T1/2 =
29 y), strontium-89 (89Sr, T1/2 = 50.6 d), and strontium-85 (
85Sr T1/2 = 65
d). Strontium-90 is a fission product associated with fallout from a
nuclear detonation and is therefore human-made. It decays via beta emis-
sion (average energy = 200 keV [maximum 546 keV]) to yttrium-90 (90Y
T1/2 = 64.1 h; average beta energy = 940 keV [maximum 2.28 MeV]).
Strontium 89 is also a beta emitter (average energy = 583 keV [maximum
1.49 MeV]). Strontium-85 mainly emits gamma rays (514 keV). The RAV
modeling approach presented below applies to each of the indicated
radiostrontium isotopes as well as to combinations of the isotopes.
Radiostrontium Metabolism in Mammals after Ingestion Exposure
Radiation doses to body organs from radiostrontium isotopes depend
on their metabolism. The metabolic behavior of radiostrontium isotopes
in humans can be described in general terms as follows (NCRP 1991):
After ingestion, a fairly substantial part (averaging between 20% and
30%) is absorbed from the gastrointestinal tract and a portion is excret-
ed unabsorbed in the feces. The absorbed portion is characterized as fol-
lows: (1) radiostrontium that deposits in the bone volume; (2) radiostron-
tium that is distributed in an exchangeable pool, which has been consid-
ered to be comprised of the plasma, extra cellular fluid, soft tissue and
bone surfaces; and (3) radiostrontium that is removed from the body by
urinary and fecal excretion.
Countermeasures after Radiostrontium Intake
A large number of studies have investigated methods of preventing
the absorption in humans of radiostrontium, while not adversely impact-
ing calcium (Ca) absorption. Information that follows in this section is
3
Scott: Calculating lethality risk avoidance
Published by ScholarWorks@UMass Amherst, 2014
Calculating lethality risk avoidance
335
based on an Agency for Toxic Substance and Disease Registry report
(ATSDR 2004). Methods for reducing the body burden of radiostrontium
that have been tested in animals include application of Ca, chelators
(with variable results), hemodialysis, and magnesium sulfate. Suggestions
for reducing absorption of radiostrontium include ingestion of antacids
containing aluminum phosphate. Treatment is most effective when initiated
within 2 h of radiostrontium exposure. Other reasonably effective strategies
have included applications of alginates and sulfates. Less effective or less
practical strategies have included a cold environment, diet, dietary fiber,
flavones, and stable Sr.
In this paper for the purpose of illustrating lethality RAV evaluation
methods, a hypothetical novel radiostrontium decorporation procedure
is considered that allows significant removal of radiostrontium from both
the skeleton and systemic circulation via the urinary pathway.
LETHALITY RISK AVOIDANCE MODELING
As already mentioned, the lethality risk avoidance modeling present-
ed here focuses on scenarios involving the ingestion intake of highly sol-
uble forms of radiostrontium (85Sr, 89Sr, 90Sr, or combinations of these).
After intake, rapid uptake to the systemic circulation is presumed with
deposition in the skeleton occurring very quickly (ATSDR 2004). To sim-
plify the examples presented below, single, negative-exponential-decaying
dose-rate patterns to bone marrow are assumed here. Theoretical results
for addressing more complex, monotonically decreasing dose-rate pat-
terns to bone marrow are presented in the Appendix. A single, negative-
exponential-decaying pattern is a reasonable assumption when >90% of
the maximum radiation dose is associated with the long-term component
of target-organ retention of radioactivity. For the skeleton, it is also a rea-
sonable assumption for short-lived, bone-seeking radionuclides ingested
in highly soluble forms because physical half-life would be the major
determinant of effective retention half-time in the skeleton.
Exposure Scenarios Considered
Two hypothetical exposure scenarios are considered that involve
large low-LET radiation doses to bone marrow from radiostrontium that
would be expected to be associated with massive cell killing in the
absence of protective radionuclide decorporation procedures (counter-
measures) being implemented. The first scenario is a single ingestion
intake (via a dietary liquid) of a radiostrontium isotope in a highly solu-
ble form followed shortly thereafter (1 h) by single application of a hypo-
thetical novel radionuclide decorporation therapy. The hypothetical
novel therapy involves two drugs: one drug stimulates the partial release
of radiostrontium from bone into the systemic circulation; the other drug
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chelates the systemic radiostrontium causing its excretion via the urinary
pathway. The second scenario is also a single ingestion intake (via a
dietary liquid) of a radiostrontium isotope followed 24 h later by single
application of the hypothetical novel decorporation therapy. The efficacy
of the decorporation therapy is presumed to be much less after a 24-h
delay than after a 1-h delay because of the larger amount of radiostron-
tium that would have been incorporated into bone by the 24-h post-intake
time point (ATSDR 2004).
Evaluating Lethality Risk
As in our previous modeling of lethality risks for radiation-induced
deterministic effects, we rely on the hazard function (HF) model devel-
oped at our Institute by this author (Scott 2004, 2005, 2007). The HF
model is quite general and can be adapted for application to a variety of
radiation exposure scenarios (Scott and Hahn 1989; Scott and Dillehay
1990; Scott et al. 1995; Scott et al. 1998; Scott and Peterson 2003; Scott
2004, 2005). The HF model has undergone extensive peer review and is
used internationally for radiological incident risk assessment by different,
widely recognized organizations. This includes use by the U.S. Nuclear
Regulatory Commission (USNRC 1998), by the Health Protection Agency
(Harrison et al. 2007), and by the International Atomic Energy Agency
(IAEA 2005).
Formal risk modeling often includes addressing dose, model param-
eter, and model uncertainties as well as variability between different indi-
viduals. Model uncertainty relates to a lack of knowledge about the appro-
priate model and can be addressed using Bayesian inference methods
(Kass and Raftery 1995). However, for the research discussed here, vari-
ability and uncertainty characterization was well beyond the scope of the research.
Only central estimates of risk (i.e., best estimates) are presented without
a discussion of related variability and uncertainty.
Hazard Function Dose-Response Model
For competing modes of death (e.g., hematopoietic, gastrointestinal,
pulmonary), the risk function R (i.e., individual probability of death) is
given as a function of the total lethality hazard, Htotal,(a cumulative haz-
ard function) and survival probability, S, by:
R = 1 - S = 1 - exp(-Htotal). (1)
Htotal represents the sum of lethality-mode-specific hazard functions
which are evaluated in a way that accounts for changing dose rate and
allows for combinations of low- and high-LET radiations (Scott and Hahn
1989; Scott 2004). Here, only a single mode of death is being assumed
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(hematopoietic) for beta/gamma-emitting radionuclides that are
retained in the skeleton and irradiate the bone marrow. In this case, Htotal
is set equal to the hematopoietic mode lethality hazard Hhem.
Evaluating the Lethality Hazard for the Hematopoietic Mode
The hematopoietic-mode lethality hazard Hhem can be evaluated in
different ways depending on the type of the exposure scenario consid-
ered. The deterministic effects relative-biological-effectiveness-weighted
dose has been used when combinations of high- and low-LET radiations
are involved (IAEA 2005). However, with beta/gamma-emitting radionu-
clides dose weighing is unnecessary (i.e., weight = 1) (Scott 2004). The risk
for acute lethality can be adequately characterized using the un-weighted,
organ-specific absorbed radiation dose rate y(t) to bone marrow at expo-
sure time t. The indicated lethality hazard is given by
Hhem = [ln(2)][∫{y(t)/D50(y(t))}dt]V = [ln(2)]XV, (2)
where the integral is evaluated over the exposure period of interest; V
(>0) is the shape parameter that determines the steepness of the dose-
response curve; and X is the corresponding normalized dose in units of
the lethality-mode-specific, median-lethal absorbed dose D50. While the
notation D50 is used here for the median lethal dose (i.e., D50 = LD50), it
can also be used for the median effective absorbed dose (ED50) for mor-
bidity endpoints (Scott 2004). Thus, Equations 1 and 2 can also be
applied to morbidity risks with HF model parameters depending on the
endpoint considered. The value X = 1 corresponds to the D50, which
increases as the dose rate decreases. Thus, for low-dose-rate exposure,
larger doses D50 (an absorbed dose here) are associated with X = 1 than
those for high-rate exposure. The cumulative absorbed radiation dose is
obtained by integrating y(t) over the exposure period of interest. For the
hematopoietic mode of death and for low-LET beta and/or gamma radi-
ation, the central estimate of V is 6 for adult humans of both sexes and is
based on Chernobyl accident victims (Scott and Hahn 1989). The indi-
cated central estimate has also been applied to all ages after birth (Scott
and Hahn 1989; Scott 2004). Uncertainty about the influence of age and
other factors on V were addressed via assigning subjective lower and
upper bounds of 4 and 8, respectively (Scott and Hahn 1989).
Usefulness of the Normalized Dose
The normalized dose (i.e., X) was introduced to address influences
of a changing dose rate and situations that involve combined exposure
to low- and high-LET radiation. The integral in Equation 2 is presented
in a num ber of publications (e.g., Scott et al. 1988, 1998; Scott 1991) and
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can be explained as follows. The product y(t)dt gives the small absorbed
radiation dose increment in the short exposure time interval (t, t+dt).
The absorbed dose increment is converted to an increment, dX, in the
normalized dose X by dividing the incremental absorbed dose y(t)dt by
D50(y(t)). These increments are added (via integration). This normalized
dose increment approach to evaluating the risk of a specific determinis-
tic effect (e.g., lethality via the hematopoietic or pulmonary mode) has
been validated by laboratory animal studies designed specifically for HF
model testing (Scott et al. 1987, 1989; Filipy et al. 1989). This includes
studies involving inhalation exposure to insoluble aerosols that contained
mixtures of alpha and beta emitting radionuclides (Scott et al. 1990). The
normalized-dose approach was also validated by applying it to data where
initial brief exposure to high-dose-rate low-LET radiation was followed
immediately by chronic low-rate exposure (Scott et al. 1998).
The dose-normalization approach was motivated by the observation
that when absorbed dose was divided by the median lethal dose for the
hematopoietic mode of death, variability related to age, species, dose
rate, and photon radiation energy was greatly reduced so that when
lethality risk was plotted vs. this normalized dose, data from a number of
different animal studies clustered around the same dose-response curve
(Figure 3 in Scott et al. 1988).
Computer codes used internationally for radiological risk assessment
employ the full HF model and related normalized doses to each critical
target organ to assess overall lethality risk (NRC/CEC 1997; Evans et al.
1993). Critical-organ-specific increments ΔX over consecutive time steps
Δt (e.g., 1-day steps) are evaluated (based on the absorbed dose incre-
ment for each time step divided by the D50 evaluated at the average dose
rate for the time step) and added to obtain an estimate of the total nor-
malized dose X. Relative biological effectiveness (RBE) weighted dose
rate (based on the RBE for the deterministic effect of interest) is used for
evaluating y(t) for combined exposure to low- and high-LET radiations
(Scott 2004; IAEA 2005). The unit of radiation dose for the combined
exposure is the gray-equivalent (Gy-Eq) (IAEA 2005).
The full HF model implemented based on normalized dose has been
used to develop an extended framework for emergency response criteria
related to radiological incidents (IAEA 2005).
The dose X is also quite useful for addressing subtle changes in dose
rate (e.g., dose rate reduction associated with applying protective decor-
poration countermeasures). For example, the normalized dose incre-
ment that occurs before applying a given radionuclide decorporation
procedure can be evaluated and added to the additional normalized dose
increment (or increments) that occurs after application of the proce-
dure. Risk is then evaluated based on the total normalized dose (i.e., the
sum of the increments). This is illustrated in this paper for hypothetical
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applications of radionuclide decorporation countermeasures. This allows
demonstrating the expected impact of different time delays of radionu-
clide decorporation therapy on its efficacy. Evaluating the normalized
dose X requires a functional relationship between D50 and the radiation
absorbed dose rate y (a fixed dose rate).
Functional Relationship between D50 and the Radiation Absorbed Dose Rate
The notation D50(y) is used here for the dose-rate dependent D50. The
D50(y) for death via the hematopoietic mode has been demonstrated to
be adequately characterized using the empirical relationship (Scott et al.
1988; Scott and Hahn 1989; NRPB 1996; USNRC/CEC 1997)
D50(y) = (θ1/y) +θ∞, (3)
that was developed for exposure to low-LET beta and/or gamma radia-
tion. Similar relationships can be applied to other lethality and morbidi-
ty risks with parameter values depending on the endpoint considered
(NRPB 1996). Beta and gamma radiations are treated as equally effective
for inducing radiation deterministic effects. The parameter θ
∞
is the
value (asymptotic value) of D50(y) at very high dose rates y. The term
(θ1/y) accounts for the steep rise in the D50 as dose rate decreases to very
low values allowing for more efficient recovery from radiation damage
than after high rates (Scott et al. 1988; Scott and Hahn 1989).
It is useful to review the development of Equation 3. Early research on
the influence of radiation dose rate on D50(y) for death via the
hematopoietic mode suggested that D50(y) decreased as a power function
of y (e.g., θy-n), where θ and n are fixed positive parameters and y is a fixed
value for the dose rate (see for example Bateman et al. 1962). According
to the indicated power function relationship, D50(y) progressively decreas-
es towards zero as the dose rate y increases (Jones 1981; Morris and Jones
1988). Thus, with extremely high but constant dose rates, even a very
small dose (near zero) could be lethal. However, our early research which
involved looking at essentially all of the then available data related to the
influence of dose rate on the median lethal dose, led us to conclude that
for high dose rate exposure, there was strong evidence for D50(y)
approaching an asymptotic value significantly greater than zero (repre-
sented by the parameter θ
∞
in Equation 3). Apparently, this phenomenon
was first observed by John Ainsworth who pointed out the observation to
me and kindly provided me with a data set on D50(y) that his research
group had generated over the years. In an acute lethality study headed by
Dr. Ainsworth, no significant difference was found in the median lethal
dose when mice received total-body exposure to external gamma rays at
60 Gy/h (body midline dose rate) when compared to that for pulsed
exposure (TRIGA Reactor) at rates in the range of 5.4x105 to 2.4x106
8
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Gy/h (Ainsworth et al. 1964). Thus, there was no significant difference in
D50(y) when the gamma-ray dose rate was increased more than 8000-fold
from the already very high value of 60 Gy/h. The observed value for
D50(y) (7.82 Gy; 95% confidence interval 7.55 – 8.18 Gy) after the ultra
high dose rate was much larger than the expected value of near zero and
not significantly different from the value obtained for the 60 Gy/h expo-
sure (7.97 Gy; 95% confidence interval 7.75 – 8.21 Gy). Similar results
were reported for dogs exposed bilaterally to 1-MeV x-rays (Ainsworth et
al. 1964). The observation of D50(y) approaching an asymptotic value >>
0 at high dose rates is here named the Ainsworth Phenomenon in honor of
his contributions during his life to the understanding of the influences of
radiation dose rate on the median lethal dose. The Ainsworth phenome-
non can be explained on the basis of all recovery processes being over-
whelmed during the period of irradiation. For exposure at very low rates,
recovery can take place during the exposure period, causing an increase
in D50(y) (Scott et al. 1988).
In our initial modeling of D50(y) vs. y, the ratio θ1/y in Equation 3 was
replaced by the construct θ1y-n, with n being a free parameter (Scott et al.
1988). The subscript 1 on the parameter θ was used to emphasize that the
parameter represents the expected increase in the D50 above its asymp-
totic value θ
∞
when y had unit value (e.g., y = 1 Gy/h). Based on the work
of Bateman et al. (1962), it was expected that n would be found to be
approximately 1/3 (i.e., a y-1/3 dependence). However, central estimates
considerably different from n = 1/3 were found in all cases where animal
data spanned the dose rate range from about 10-2 to 10-1 Gy/h (Scott et al.
1988). Central estimates for n and their associated standard deviations for
swine, dogs, goats, and sheep were 0.9 ± 0.1, 0.8 ± 0.1, 1.1± 0.3, and 1.0 ±
0.5, respectively (Scott et al. 1988). Data for rats, and mice did not span
the dose rate range of interest and were considered not to be suitable for
estimating n. The average of the central estimates of n for swine, dogs,
goats, and sheep was 0.95 ± 0.13 or approximately 1, implication θ1y-1 =
θ1/y for use in Equation 3 (Scott et al. 1988). Thus, Equation 3 has been
employed since the 1980s and has been used for a variety of determinis-
tic effects (see for example NRPB 1996 and IAEA 2005).
Table 1 presents estimates (central and associated standard deviation)
of model parameters θ1 and θ∞ derived using available data for uniform
gamma or high-energy x-ray exposure of different mammals (rats, mice,
swine, dogs, goats, sheep, and humans) and is based earlier publications
(Scott and Hahn 1989; Scott and Dillehay 1990). No standard deviation
is provided in the table for the parameter estimates for humans because
of the way they were derived. Information on uncertainty for these
parameters is provided below. Values in Table 1 apply to circumstances
where no supportive medical care is provided. The indicated values for θ1
and θ
∞
are highly correlated (R2 = 0.94, p < 0.001).
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For the hematopoietic mode of death and for low-LET beta and
gamma radiation, central estimates for HF model parameters for humans
are θ
∞
= 3.0 Gy and θ1 = 0.07 Gy2/h and are based on data and informa-
tion related to humans that were exposed briefly (at high rates) or chron-
ically (at low rates) to low-LET radiation (Scott and Hahn1989). The 3 Gy
estimate is similar to the two estimates (2.9 Gy and 3.4 Gy) developed by
Levin et al. (1992) via fitting two different dose-response models to acute
lethality data for human occupants of reinforced concrete structures in
Nagasaki, Japan at the time of the atomic bomb detonation.
Subjective lower and upper bounds for θ
∞
for the hematopoietic mode
of death in humans have been developed and are presumed to account for
uncertainty about the influence of age, gender, and other factors. The
lower and upper bounds are 2.5 and 3.5 Gy, respectively (Scott and Hahn
1989). The corresponding bounds for θ1 are 0.06 and 0.08 Gy2/h, respec-
tively (Scott and Hahn 1989). The impact of the indicated HF model
parameters uncertainty on risk assessment reliability has been addressed
in other publications (USNRC/CEC 1997; Scott and Peterson 2003).
To account for the influence of supportive medical care provided to
radiation victims, the model parameters θ1 and θ∞ are increased by a fixed
multiplication factor (protection factor [PF]) (Scott 1991, 2005). The cen-
tral estimate of the PF for the hematopoietic mode of death and for sup-
portive medical treatment that was developed during the 1990s was 1.5
(Scott 1991; Evans et al. 1993). A larger value may apply today given the
advancements that have been made in treating radiation injuries.
Parameter estimates in Table 1 [based on Scott et al. (1988), Scott and
Dillehay (1990) and on Scott and Hahn (1989) and Equation 3] were
used to compare D50(y) values for the hematopoietic mode of death for
different mammals (rats, mice, dogs, swine, goats, sheep, and humans)
that were exposed to high-energy ionizing photon radiation at different
TABLE 1. Estimates of θ1 and θ∞ for the hematopoietic mode of death for different mammal
species for low-LET radiation (beta and/or gamma) when no medical support is provided, based
on Scott and Dillehay (1990) and Scott and Hahn (1989). 
Species θ1 (Gy2/h) θ∞ (Gy)
Rata 1.07 ± 0.30 10.9 ± 1.42
Mouseb 0.49 ± 0.13 6.5 ± 0.47
Dog 0.11 ± 0.004 2.69 ± 0.13
Swine 0.29 ± 0.008 2.45 ± 0.10
Goat 0.073 ± 0.006 2.52 ± 0.35
Sheep 0.0027 ± 0.003 1.68 ± 0.10
Humanc 0.07 3.0
aFemale albino Sprague-Dawley rats.
bWhite non-inbred mice.
cOnly data for individuals or group presumed to be of normal susceptibility to irradiation were
used to obtain the indicated parameter estimates (Scott and Hahn 1989).
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dose rates. Predicted values for the D50 vs. dose rates of 0.01, 0.1, 1, 10,
and 100 Gy/h are presented in Figure 1. Note that the Ainsworth
Phenomenon is clearly shown at high dose rates for each of the different
species. In each case, the asymptotic value for D50(y) exceeded 1.5 Gy
(1,500 mGy) (see values for θ
∞
in Table 1). Note also that similar esti-
mates of D50(y) were obtained for dogs, goats, and humans, indicating (as
previously recognized [Scott et al. 1988]) that dogs and goats might be
suitable surrogates for humans when studying radiation toxicity to the
hematopoietic system. Dogs are also considered a good animal model
(surrogate for humans) for studying the biokinetics of bone-seeking
radionuclides such as 85Sr and 90Sr. Results presented in Figure 1 are
expected to also apply to low-LET beta radiation or mixtures of beta and
gamma radiations (Scott and Hahn 1989).
The HF model has also been applied to lethality risk evaluation for
exposure to high-LET alpha radiation or to mixtures of high-LET alpha
and low-LET beta and gamma radiations. For combined exposures to low-
and high-LET radiations, RBE-weighted dose (e.g., in Gy-Eq) has been
used as mentioned above.
For exposure to mainly alpha radiation from 210Po (or other alpha
radiation sources), HF model parameters developed for low-LET radiation
can be adjusted for direct applications to high-LET radiation (Scott 2007).
To make the adjustment, θ
∞
should be divided by the RBE for alpha radi-
ation relative to gamma rays and θ1 should be divided by RBE2 (i.e., the
square of RBE) (USNRC/CEC 1997; Harrison et al. 2007; Scott 2007).
Analytical Solution for X for Single, Negative-Exponential-Decaying Dose Rate
The following analytical solution for the dose X in Equation 2 was pre-
viously published (using somewhat different notation) for a single nega-
tive-exponential-decaying dose-rate pattern to bone marrow with initial
dose rate A and decay parameter λ (Scott and Dillehay 1990):
X {t, A} = [D {t, A}/θ
∞
] - (θ1 ln{[Aθ∞ + θ1]/[Aθ∞ exp(-λt) + θ1]})/λθ∞2. (4)
D {t, A} is the exposure-time-dependent radiation absorbed dose to the
target organ at exposure time t and is evaluated as (A/λ )[1 - exp(-λt)]
for the dose-rate pattern considered here. Here A is evaluated as the dose
rate to bone marrow shortly after uptake of radiostrontium from the sys-
temic circulation. This is a reasonable assumption for intake via ingestion
or inhalation when in a highly soluble form. The parameter λ relates to
the effective retention half-time (T1/2) of the radionuclide in bone
according to the equation λ = [ln(2)]/T1/2. The parameter λ is the sum
of two components (λp for physical decay and λb for biological removal).
For short-lived radionuclides that are avidly retained in the skeleton (e.g.,
for 85Sr and 89Sr), λb << λp, so that λ ≈ λp. For a population of humans and
11
Scott: Calculating lethality risk avoidance
Published by ScholarWorks@UMass Amherst, 2014
Calculating lethality risk avoidance
343
for bone seeking radionuclides such as radiostrontium, λb is known to
vary for different individuals (ASTDR 2004). The variability may in part
relate to variations in gene sequences that impact on bone mineralization
and remodeling processes. Influential polymorphisms in the indicated
genes as well as other genes could lead to altered radionuclide biokinet-
ics. There is a need for a new international research initiative related to
genetics-based radionuclide (GBR) biokinetics modeling.
The term D {t, A}/θ
∞
in Equation 4 can be replaced with Xmax{t, A}
(value of X {t, A} when recovery is overwhelmed during high-rate expo-
sure) and the term following the negative sign can be replaced with Q {t,
A}. The function Q {t, A} is called the normalized dose adjustment
(NORDA). The NORDA is due to the body’s protective measures (e.g.,
repopulation of lost bone marrow cells and repair of DNA damage) that
FIGURE 1. Predicted median lethal dose (D50(y)) for the hematopoietic mode of death for different
mammals (rats [Sprague-Dawley], mice [white, non-inbred], dogs, swine, goats, sheep, and humans)
as a function of the external low-LET radiation dose rate y to bone marrow in Gy/h. For each species,
D50(y) is predicted to approach an asymptotic value > 1.5 Gy (1,500 mGy) as dose rate becomes large
(Ainsworth Phenomenon). Dose rate is presented as a categorical variable and is not aligned to tick
marks. 
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come into play when the dose rate is low, making the normalized dose
shrink from its maximum value Xmax{t, A} that occurs when dose rate is
high. This leads to the following useful equation:
X {t, A} = Xmax{t, A} - Q {t, A}. (5)
An equation analogous to Equation 5 is utilized in the Appendix to
obtain results for application to any type of dose-rate pattern that monot-
onically decreases with time. For very high dose rates, there is little to no
opportunity for recovery from damage during irradiation so that the
NORDA (i.e., Q {t, A}) approaches zero as dose rate becomes very large
and the normalize dose essentially equals Xmax{t, A}.
Asymptotic Solution for Normalized Dose
Over time and for a single, negative-exponential-decaying dose-rate
pattern, X {t, A} will approach an asymptotic value X
∞
{A} (i.e., asymptotic
normalized dose) that can be obtained by taking the limit of X {t, A} (based
on Equation 5) as t → ∞. This limit is given by the following:
X
∞
{A} = (D
∞
{A} /θ
∞
) - Q
∞
{A}. (6)
The new terms on the right-hand side of the equations represent the
following asymptotic relationships:
D
∞
{A} = A/λ (7)
and
Q
∞
{A} = [θ1 ln{(Aθ∞ + θ1)/(θ1)}]/λθ∞2 (8)
The absorbed dose D
∞
{A} represents what historically has been called
the infinite dose (the committed dose evaluated over all times). The term
Q
∞
{A} is the maximum value for the NORDA for a single, negative-expo-
nential-decaying dose-rate pattern. The dose X
∞
{A} when evaluated
according to Equation 6 will be linearly related to T1/2, because λ (which
is inversely related to T1/2) appears in the denominator of both Equations
7 and 8.
Figure 2 shows the central estimate of X
∞
{A} for a range of initial dose
rates A to bone marrow when T1/2 = 50, 100, or 1000 d. A value of T1/2 =
50 days would be expected to be representative of 89Sr because it is a
short-lived radionuclide with a physical half-life of 50.6 d. For short-lived
radionuclide avidly retained in the skeleton, the effective retention half-
time should be similar to the physical half-life.
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Determining the Period over Which Radiation Dose Should Be Evaluated
Plotting X{t, A} vs. radiation exposure time t is a useful way for deter-
mine the period over which radiation dose should be evaluated when
assessing lethality risks for inhaled and ingested radionuclides. This period
will depend on the initial dose rate A, the parameter λ (or alternatively
T1/2), and parameters θ∞ and θ1. The value of X {t, A} will increase initially
and later approach the asymptotic value X
∞
{A}. Figure 3 shows the expect-
ed temporal pattern of build up of X {t, A} in humans for the hematopoiet-
ic mode of lethality for T1/2 = 50, 100, and 1,000 d when A = 0.01 Gy/h
when follow-up is to 500 d after radiostrontium intake. For points of refer-
ence, an estimate of the population threshold for lethality is X
∞
{A}= 0.5 (R
= 0.01 for the hematopoietic mode of death) and an estimate of the dose
that would be fatal for all exposed persons is X
∞
{A} = 1.5 (See Table 2).
Special consideration needs to be given to the time period over which
radiation dose is evaluated when assessing lethality risks for ingested (or
inhaled) radionuclides. Preparing a table of values of X {t, A}/X
∞
{A} vs.
t/T1/2 (normalized time in units of T1/2) is a useful way of determining
FIGURE 2. Central estimates of the asymptotic normalized dose X
∞
{A} for the hematopoietic mode
of death in humans for a single, negative-exponential-decaying, dose-rate pattern of beta and/or
gamma radiation to bone marrow of humans. Results are presented for different initial dose rates A
and for three effective retention half-times: 50 d (diamonds), 100 d (squares), and for 1000 d (tri-
angles). 
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the period over which radiation dose should be evaluated when assessing
lethality risks for single negative-exponential-decaying, dose-rate pat-
terns. Exploratory analyses revealed that for a given set of HF model
parameters the results one gets is determine by the value assigned to nor-
malized time. Thus, altering both t and T1/2 by the same factor (e.g., fac-
tor of 2 increases for both) yields the same result. Because the value of
X {t, A} increases with increasing t and eventually approaches the asymp-
totic value X
∞
{A}, the ratio X {t, A}/X
∞
{A} will eventually approach the
asymptotic value of 1.0. The lethality risk R will be expected to increase
so long as X{t, A}/X
∞
{A} increases.
Table 3 provides results for the ratio X {t, A}/X
∞
{A} vs. t/(T1/2) for the
hematopoietic mode of death for radiostrontium incorporated into the
skeleton. Results are specific for single negative-exponential-decaying
dose rate patterns and for A = 0.001, 0.002, 0.004, 0.006, 0.008, or 0.01
Gy/h. The results are weakly dependent on A and are strongly depend-
ent on normalize time (i.e., t/T1/2). Based on the results presented in
Table 3, most of the lethality risk accumulation would be expected to
FIGURE 3. Central estimates of the temporal pattern of build-up of the normalized dose X{t, A} for
the hematopoietic mode of death in humans when radiation dose rate to bone marrow decreases as
a single, negative-exponential-decaying pattern over time after intake of a bone-seeking radionuclide
that emits beta and/or gamma radiation. Results are presented for an initial dose rate of 0.01 Gy/h
and for three effective retention half-times: 50 d (diamonds), 100 d (squares), and for 1000 d (tri-
angles). 
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have occurred by the time t for which t/T1/2 = 4. This time is given by
4T1/2 which for example would be 400 d after radionuclide intake when
T1/2 = 100 d. Thus, for short-lived radionuclides that are ingested in a
highly soluble form, the asymptotic value for the normalized dose will be
reached rather quickly. For long-live radionuclides that are ingested in a
highly soluble form, it may take more than a year for the asymptotic value
to be achieved.
For multiple negative-exponential-decaying, dose-rate patterns, the
product 4T1/2 can be evaluated based on the long-term retention compo-
nent. However, the more involved procedure presented in the Appendix
is then needed for evaluating the normalized dose.
Evaluating the Normalized Dose Increment that Occurs Before and After
Application of Decorporation Countermeasures
The dose increment, X {t, A}, that occurs before application of decor-
poration countermeasures for radiostrontium after intake as a result of a
radiological terrorism incident can be evaluated using the following
equation, where t = T is the time at which the single decorporation treat-
ment is applied:
X {T, A} = Xmax{T, A} - Q {T, A}. (9)
Equation 9 is the same as Equation 5 with T having replaced t.
TABLE 2. Central estimates of the lethality risk for the hematopoietic mode of death in humans as
a function of the asymptotic value of the normalized dose. 
Dose X
∞
{A}a Lethality Risk
0 0
0.4 0.00284
0.5a 0.0108
0.6 0.0318
0.7 0.0783
0.8 0.166
0.9 0.308
1.0 0.5
1.1 0.707
1.2 0.874
1.3 0.965
1.4 0.995
1.5 1.0
aA value of X
∞
{A} = 0.5 (lethality risk ≅ 0.01) has been used as an estimate of the threshold expo-
sure in radiological risk assessment because of the steepness of the dose-response curve for the lethal-
ity risk (Scott 2004). A values of X
∞
{A} = 0.4 (lethality risk ≅ 0.003) may be preferred for the thresh-
old estimate for some applications.
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The increment in the normalized dose that occurs after application
of protective decorporation countermeasures depends on the scenario
considered. It is assumed that the lethality risk associated with the coun-
termeasures application is negligible. Thus, only risk associated with radi-
ation exposure is addressed. As already indicated, we consider applica-
tion of two hypothetical novel drugs that cause release of radiostrontium
from bone (drug 1) facilitating its removal via chelation (drug 2) from
the body. The dose increment X
∞
{Aalt(T)} that occurs after application of
decorporation countermeasures for radiostrontium after intake is evalu-
ated using the asymptotic solution in Equation 6, after calculating the
altered dose rate Aalt(T) to bone marrow at time T resulting from having
applied the decorporation countermeasures. In this hypothetical exam-
ple, the early dose rate to bone marrow is on average quickly reduced by
a decorporation-time-dependent dose-rate-reduction factor (DRRF) given by
DRRF(T), and the pattern of decline in dose rate afterward is presumed
TABLE 3. Ratio X {t, A}/X
∞
{A} vs. t/(T1/2) for the hematopoietic mode of death for radiostrontium
incorporated into the skeleton.a
Initial Dose Rate
t/(T1/2) 0.001
b 0.002b 0.004b 0.006b 0.008b 0.01b
0 0 0 0 0 0 0
0.1 0.128 0.126 0.124 0.121 0.119 0.117
0.2 0.240 0.237 0.232 0.228 0.224 0.221
0.4 0.422 0.419 0.412 0.406 0.400 0.395
0.6 0.561 0.557 0.550 0.543 0.537 0.531
0.8 0.667 0.663 0.656 0.650 0.644 0.638
1 0.747 0.744 0.738 0.732 0.726 0.721
1.2 0.808 0.805 0.800 0.795 0.790 0.785
1.4 0.855 0.852 0.848 0.843 0.839 0.835
1.6 0.890 0.888 0.884 0.881 0.877 0.874
1.8 0.917 0.915 0.912 0.909 0.906 0.904
2 0.937 0.936 0.933 0.931 0.929 0.927
2.2 0.953 0.952 0.950 0.948 0.946 0.944
2.4 0.964 0.963 0.962 0.960 0.959 0.958
2.6 0.973 0.973 0.971 0.970 0.969 0.968
2.8 0.980 0.979 0.978 0.978 0.977 0.976
3 0.985 0.985 0.984 0.983 0.983 0.982
3.2 0.989 0.989 0.988 0.988 0.987 0.987
3.6 0.994 0.994 0.994 0.993 0.993 0.993
3.8 0.996 0.996 0.995 0.995 0.995 0.995
4 0.997 0.997 0.997 0.997 0.996 0.996
4.25 0.998 0.998 0.998 0.998 0.998 0.998
4.5 0.999 0.999 0.999 0.999 0.999 0.999
4.75 1.000 1.000 1.000 1.000 1.000 0.999
5 1.000 1.000 1.000 1.000 1.000 1.000
aResults presented are determined by the ratio t/T1/2 and apply to all single, negative-exponen-
tial-decaying, dose-rate patterns for the range of initial dose rates presented.
bGy/h.
17
Scott: Calculating lethality risk avoidance
Published by ScholarWorks@UMass Amherst, 2014
Calculating lethality risk avoidance
349
still to be a single negative exponential with parameter λ. The altered
dose rate just after radiation time t = T is therefore given by the following:
Aalt(T) = A exp(-λT)/DRRF(T). (10)
Equation 10 provides the new initial dose rate for the time interval
being considered. The variable A in Equation 6 is therefore replaced by
Aalt(T) to obtain the dose increment (an asymptotic solution):
X
∞
{Aalt(T)} = [Aalt(T)/(λθ∞)] - [θ1 ln{(Aalt(T)θ∞ + θ1)/(θ1)}]/λθ∞2 (11)
or
X
∞
{Aalt(T)} = (D∞{Aalt(T)}/θ∞) - Q∞{Aalt(T)}. (12)
The total normalized dose long after protective radionuclide decor-
poration countermeasures are applied is represented by Xpro and is given
by the following:
Xpro = X {T, A} + X∞{Aalt(T)}. (13)
The term X {T, A} in Equation 13 is the increment in the normalized
dose that occurs before applying decorporation therapy and the term
X
∞
{Aalt(T)} is the increment that occurs after the therapy is applied. The
subscript pro stands for protective radionuclide decorporation. Lethality
risk avoidance can now be estimated based on Xpro (Equation 13), X∞{A}
(asymptotic normalized dose when no countermeasures are applied),
and Equation 1.
Evaluating Lethality Risk Avoidance Due to Protective Decorporation
Countermeasures
The total hematopoietic-mode-lethality risk (central estimate) with-
out decorporation countermeasures is indicated as Runpro and is given by
the following:
Runpro = 1 - exp{[-ln(2)]X∞{A}
6}. (14)
The subscript unpro stands for unprotected. The corresponding risk
(central estimate) when protective decorporation countermeasures are
applied at time T is indicated as Rpro and is given by the following:
Rpro = 1 - exp{[-ln(2)]Xpro
6}. (15)
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The central estimate of the lethality RAV can therefore be evaluated
as follows:
RAV = Runpro - Rpro. (16)
The corresponding equation for the lethality RAP is as follows:
RAP = RAV/Runpro. (17)
In order to apply the above equations to real world scenarios, one
needs a plausible value for T1/2. The long-term retention of radiostron-
tium [presumably skeletal retention (ATSDR 2004)] has been studied in
humans who were exposed to 90Sr in the Techa River area of Russia after
fission products from a plutonium production process were released into
the river. Techa River water and foods contaminated with radionuclides
from the river were sources of the human exposures. Whole-body reten-
tion half-times for radiostrontium were estimated in a study population of
361 males and 356 females to be 28 y (central estimate) in males and 16
y (central estimate) in females (Tolstykh et al. 1997). Most of the differ-
ence in the retention half-times estimated for males and females is pre-
sumed to have resulted from a pronounced increase in the elimination
rate in females after age 50 y (Tolstykh et al. 1997).
For applications of the above equations, a value of T1/2 = 16 y has been
used for a hypothetical group of female children under the age of 16 y.
This choice is to ensure that the asymptotic solutions derived can justifi-
ably be employed. For T1/2 > about 25 y, the asymptotic solutions may
overestimate risk (although not necessarily, depending on the initial dose
rate), as a significant part of the calculated radiation dose would occur
after the end of the life expectancy. This extra dose, however, may be asso-
ciated with very low dose rates so that there is no significant contribution
to the normalized dose and calculated lethality risk.
For lethality RAV and RAP evaluations for the hematopoietic mode of
death after ingesting radiostrontium, two subjective values of DRRF were
considered: DRRF = 10 (dramatic protection when the radionuclide
decorporation therapy is administered 1 h after radionuclide intake) and
DRRF = 2 (modest protection when radionuclide decorporation therapy
is applied 24 h after radionuclide intake). The radionuclide decorpora-
tion therapy considered here is for a single application. Equations are
provided in the Appendix that can be applied to multiple applications
over time of radionuclide decorporation therapy.
The results (central estimates) obtained for the hematopoietic mode
lethality RAV are presented in Figure 4. The initial dose rate was allowed
to range from 0.0001 to 0.004 Gy/h. Note that calculated results were the
same whether radionuclide decorporation therapy was given at 1 h or at
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24 h when the initial dose rate was < 0.001 Gy/h. However for an initial
dose rate >0.001 Gy/h, the lethality RAV progressively decreased toward
zero as the initial dose rate increased to just above 0.002 Gy/h for the
24-h decorporation therapy results but not for the 1-h decorporation
therapy results.
The corresponding results (central estimate) obtained for the
hematopoietic mode lethality RAP are presented in Figure 5 and are bet-
ter indicators of the efficacy of radiation countermeasures (related to risk
reduction) than are the RAV results. For initial dose rates <0.001 Gy/h,
essentially all of the lethality risk was calculated as being avoided (i.e.,
RAP = 1) by the radionuclide decorporation therapy whether adminis-
tered at 1 h or 24 h after intake of radiostrontium. This dose-rate zone is
called the green zone (essentially all of the lethality risk is expected to be
avoided, i.e., RAP = 1). For initial dose rate >0.001 Gy/h but < 0.002 Gy/h,
the efficacy of the decorporation therapy (with respect to lethality risk
reduction) progressively decreased toward zero (i.e., towards RAP = 0)
as the initial dose rate increased toward 0.002 Gy/h for the calculated
24-h decorporation therapy results. For the case of the 24-h post
radiostrontium intake application of countermeasures, this dose rate
FIGURE 4. Central estimate of the hematopoietic mode lethality RAV for young (<16 y) female
humans that ingest radiostrontium in a highly soluble form and afterwards receive radionuclide
decorporation therapy (hypothetical) at 1 h (diamonds) or 24 h (squares) after intake of the radioac-
tive substance. Evaluations were carried out for DRRF(1 h) = 10 (diamonds) and for DRRF(24 h) = 2
(squares) for a range of initial dose rates to bone marrow when T1/2 = 16 y. The two curves overlap
for initial dose rates <0.001 Gy/h. 
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zone is considered the yellow zone (zone for which some but not all of the
lethality risk is expected to be avoided, i.e., 0 < RAP < 1). For the case for
the 1-h post radiostrontium intake application of countermeasures, the
results, indicate an expected complete avoidance of all the lethality risk
(i.e., RAP = 1) for the range of initial dose rate indicated. Thus, for this
decorporation scheme, the green zone is extended at least up to an ini-
tial dose rate of 0.004 Gy/h. However, for the 24-h post radiostrontium
intake decorporation scheme, initial dose rate > 0.002 Gy/h would be
expected to be lethal for everyone (no lethality risk avoided since RAP =
0). This dose rate zone is called the red zone, as none of the lethality risk
(Runpro = 1) is expected to be avoided (Rpro = Runpro = 1).
The results presented here relate to a single, negative-exponential-
decaying dose-rate pattern. Such a pattern may not apply to some real
world situations (e.g., long-lived bone seeking radionuclides), as available
data (ATSDR 2004) indicate that for 90Sr early clearance is more rapid
than the later clearance (long-term retention T1/2 > 15 y). For such cir-
cumstances, the results presented in the Appendix can be applied that
allow evaluating exposure-time-dependent increments, X {t, Δt, z(t)}, in
the normalized dose over small exposure time increments (t, t + Δt) for
FIGURE 5. Central estimates of the hematopoietic mode lethality RAP for young (<16 y) female
humans that ingest radiostrontium in a soluble form and afterwards receive radionuclide decorpo-
ration therapy (hypothetical) at 1 h (diamonds) or 24 h (squares) after intake of the radioactive sub-
stance. Evaluations were carried out for DRRF(1 h) = 10 (diamonds) and for DRRF(24 h) = 2
(squares) for a range of initial dose rates to bone marrow when T1/2 = 16 y. The two curves overlap
for initial dose rates <0.001 Gy/h. 
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any monotonically decreasing dose-rate pattern to bone marrow (or
other organs). The function z(t) is the radiation absorbed dose rate at
time t when the impact of radionuclide decorporation is accounted for.
The approach presented in the Appendix is a generalization of what is presented
here and could be used to design optimal radionuclide decorporation schemes and
to identify dose rate zones (green, yellow, and red) for a given decorporation sched-
ule. Boundaries for the indicated dose rate zones will depend on the
exposure/counter-measures scenario considered.
Using the indicated computational procedures, along with a reliable
computer code (e.g., Eckerman 2006) that evaluates radiation absorbed
doses and dose rate to key body organs and tissue, allows for a more for-
mal risk assessment related to evaluating lethality RAV and RAP; however,
such an undertaking is beyond the scope of our current research.
The research described here is an extension of much earlier research
conducted by the author. Unfortunately support for continuing the earlier
research disappeared some years ago and interest in supporting the type of
theoretical/modeling research presented in this paper has not increased
since that time. Unless more appreciation is develop by the scientific com-
munity of the important contributions that theoretical/modeling research
can make to the advancement of scientific knowledge related to planning
for and managing radiological terrorism incidents, the next generation of
scientist may be devoid of essential knowledge needed for addressing the
types of issues that are addressed in this paper.
CONCLUSIONS
This paper provides a theoretical framework for evaluating hematopoi-
etic-mode lethality RAV and RAP that were designed to facilitate planning
for and managing radiological terrorism incidents that involve the inges-
tion intake by humans of large quantities of bone-seeking beta/gamma-
emitting radionuclides. The lethality RAP when evaluated as outlined could
be used in developing optimal radionuclide decorporation schemes and
for identifying green, yellow, and red dose-rate zones for a given decorpo-
ration scheme. For the green dose-rate zone, essentially all of the lethality
risk is expected to be avoided (RAP = 1) as a consequence of the radionu-
clide decorporation scheme used. For the yellow zone, some of the risk is
expected not to be avoided (0 < RAP < 1) for the decorporation scheme
used. For the red zone, none of the lethality risk is expected to be avoided
(RAP = 0 and Rpro = Runpro = 1) for the decorporation scheme used.
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APPENDIX
More Complex, Monotonically Decreasing, Dose-Rate Patterns
A similar approach as described in the main text of this paper can be
employed for any monotonically decreasing, dose-rate pattern to bone
marrow using the generalized results presented below, where y(t) is the
unmodified dose rate at radiation exposure time t. Relationships are pro-
vided that allow for evaluating small increments in the normalized dose
over consecutive, relatively short radiation exposure time intervals (t, t +
Δt). To address departure from a single, negative-exponential-decaying
pattern of dose rate, the parameter λ is replaced by a time-dependent
function λ(t) that allows for a changing rate of radioactivity loss as time
increases.
To account for the impact on dose rate of applying radionuclide
decorporation procedures (single or multiple applications), the dose rate
y(t) is adjusted downward by the radiation-exposure-time-dependent
DRRF(t), where the altered radiation absorbed dose rate z(t) is given by
z(t) = y(t)/DRRF(t). (A1)
Prior to application of any decorporation therapy, DRRF(t) = 1; other-
wise DRRF(t) > 1. This leads to the following relationships for the exposure-
time-dependent increment, X {t, Δt, z(t)}, in the normalized dose over the
interval (t, t + Δt) (e.g., Δt = 1 d for long-lived radionuclides):
X {t, Δt, z(t)} = {z(t)[1-exp(-λ(t)Δt)]/[λ(t)θ
∞
]} – 
(θ1/[λ(t)θ∞2])ln{[z(t)θ∞ + θ1]/[ z(t)θ∞ exp(-λ(t)Δt) + θ1]}. (A2)
The decay function λ(t) in the above equation is evaluated as follows:
λ(t) = - [ln{ z(t + Δt)/z(t)}]/Δt. (A3)
The use of the function DRRF(t) as indicated in Equation A1 impos-
es a constraint on its values. The constraint is that DRRF(t2) ≥ DRRF(t1)
when t2 > t1. The constraint is necessary because DRRF(t) acts on y(t)
which relates to the dose-rate pattern when no radionuclide decorpora-
tion measures have been used. Thus, if at time t1 dose rate is reduced by
a factor of two because of decorporation countermeasures applied and at
time t2 the already altered dose rate is reduced also by another factor of
2 due to additional decorporation countermeasures, then DRRF(t1) = 2
and DRRF(t2) = 4. For this hypothetical example, z(t1) = y(t1)/2 and z(t2)
= y(t2)/4.
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It is important that when z(t) is expressed in Gy/h that t be expressed
in h, θ1 be expressed in Gy2/h, and θ∞ be expressed in Gy. For the single,
negative-exponential-decaying dose-rate pattern A exp(-λt), the right-
hand side of Equation A3 yields λ.
At the interval for which the last countermeasure is applied at time T,
the asymptotic solutions presented in the main text can be used with the
dose rate Aalt(T) replaced by z(T) which equals y(T)/DRRF(T). The last
increment in the normalized dose will then be expressed as X
∞
{z(T)}. All
of the normalized dose increments then can be added to obtain the total
normalized dose Xpro and applied in Equations 16 and 17 when evaluat-
ing the RAV and RAP. For cases where the long-term retention half-time
in the target organ is more than 25 y, using the asymptotic solutions may
lead to overestimation of risk. In such cases Equations A1, A2 and A3 can
be repeatedly used over whatever follow-up time is desired.
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